JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100®
10 August 2023 - 10:00PM
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume
measurement technology, today announces a research letter in the
Journal of the American College of Cardiology – Heart Failure
reporting on the successful results of a pilot 31 patient
randomized control trial (RCT) conducted by the Duke Clinical
Research Institute utilizing Daxor’s BVA-100 diagnostic to measure
clinician assessment accuracy and the impact of optimizing
decongestion therapy for heart failure patients with the
diagnostic.
The study results showed that all patients had
marked volume derangements, but that in over 68% of the cases care
teams did not correctly diagnose the volume state of the patient by
clinical exam when compared to BVA. Marat Fudim, M.D., principal
investigator concluded, “Physician judgment of congestion status is
not an accurate representation of actual blood volume. Our findings
support the feasibility of randomized trials of BVA-guided heart
failure therapy and our encouraging findings support a future,
large, multicenter RCT to further investigate the effect of BVA
measurement clinical outcomes.”
The study showed that utilizing the BVA-100
early in patient admission in the setting of a heart failure RCT
was practical, but that optimization of the process would be part
of a larger study trial design. Other measured outcomes such as
patients in the control group being treated more effectively to an
optimal volume, and being discharged after shorter lengths of stay
were noted by researchers, but the findings did not reach
statistical significance due to the small sample size of the study
population.
“This pilot RCT provides further evidence that
Daxor’s technology is a practical and effective solution to the
challenge of optimizing heart failure care,” said Michael
Feldschuh, Daxor’s CEO and President. “This first-of-its-kind RCT
adds further validation to existing clinical use of our diagnostic
in heart failure and confirms that surrogate markers such a
physical exam are not accurate or precise compared to direct and
objective measurement with Daxor’s BVA system. Daxor will continue
to work toward larger randomized trials building on the evidence
published by these and other researchers.”
Link to Research Letter HERE.
About Daxor Corporation
Daxor Corporation (NASDAQ: DXR), is the
global leader in blood volume measurement technology focused on
blood volume testing innovation. We developed and market the
BVA-100® (Blood Volume Analyzer), the only diagnostic blood
test cleared by the FDA to provide safe, accurate, objective
quantification of blood volume status and composition compared to
patient-specific norms. Over 65,000+ tests have been performed at
leading hospital centers across the U.S., enhancing hospital
performance metrics in a broad range of surgical and medical
conditions, including significantly reducing mortality and
readmissions in heart failure and critical care. Daxor has several
ongoing trials in the areas of heart failure treatment with support
from the NIH and is under contract developing analyzers to improve
combat casualty care with the U.S. Department of Defense. Daxor's
mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com. Sign up to receive news on Daxor’s
innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Historical Stock Chart
From Apr 2024 to May 2024
Daxor (NASDAQ:DXR)
Historical Stock Chart
From May 2023 to May 2024